EVIDENCE MATRIX / FOUR GENERATIONS
The Molecules Differ. So Do the Questions They Can Answer.
A side-by-side reading of origin, engineered persistence, mechanism, human evidence, and the gap that remains for each compound.
The short version
This is not a contest between four substitutes. MOTS-c, NAD+, semaglutide, and CJC-1295 act in different systems and were studied for different purposes. The useful comparison is how a biological idea travels toward evidence. MOTS-c begins as a newly recognized mitochondrial signal with strong cell and animal work but no human efficacy trial [1][3][6]. NAD+ is a core coenzyme, not a peptide; precursor trials show that its blood level can be raised, while broad health benefits remain uncertain [8][9][12]. Semaglutide is a modified gut-hormone analogue with large human trials measuring weight and clinical events [14][15][16]. CJC-1295 is a modified hormone-releasing fragment with early human studies proving hormonal activity but not long-term benefit [20][21][22].
The comparison therefore runs on two axes: what was engineered and what was measured. A compelling mechanism can justify a trial. It cannot replace one. A changed biomarker can confirm target engagement. It cannot stand in for a health outcome.
The evidence matrix
| Dimension | MOTS-c | NAD+ | Semaglutide | CJC-1295 |
|---|---|---|---|---|
| Molecular class | Mitochondrial-derived peptide | Redox coenzyme, not a peptide | Modified GLP-1 peptide analogue | Modified GHRH fragment |
| Design story | Endogenous signal discovered inside mitochondrial DNA | Endogenous cellular currency; precursors replenish the pool | Protease resistance plus albumin binding extends a gut-hormone signal | Protease resistance plus DAC albumin attachment extends a pituitary signal |
| Main target or pathway | AMPK, NRF2 stress response, direct CK2 interaction [1][5][6] | Redox reactions; sirtuins, PARPs, and CD38 [11] | GLP-1 receptor in pancreas, brain, and gut | Pituitary GHRH receptor and downstream growth hormone/IGF-1 axis [18] |
| Human evidence maturity | Observational biomarker association; no efficacy trial [2] | Controlled precursor trials; clinical translation inconsistent [8][9][10][12] | Large randomized outcomes trials [14][15][16] | Small early pharmacology studies [20][21][22] |
| Central uncertainty | Whether administered peptide benefits people | Whether higher NAD+ produces durable clinical benefit | How benefits and known risks balance for an individual clinical context | Whether sustained GH/IGF-1 stimulation is beneficial and safe long term |
| Regulatory frame | Research-only; not approved | Supplements and compounded wellness products vary by form and status | Approved prescription medicine in specific formulations and indications | Research-only; not approved |
First generation: discovering endogenous signals
MOTS-c represents discovery. Its importance lies in the source of the message: a peptide encoded within mitochondrial genetic material that can participate in stress signaling toward the nucleus [3][5]. Work in model systems connects it with AMPK activation, glucose handling, exercise response, and CK2 [1][4][6]. The science changes how mitochondria are understood, but the therapeutic inference remains speculative because intervention data in people are missing.
NAD+ is more ancient and more fundamental. It is already embedded in cellular energy transfer and enzyme signaling [11]. Here, the intervention strategy is not to invent a receptor agonist but to replenish a pool through precursors. The human trials verify biochemical movement and report selected functional findings [9][10][12]. The unresolved step is connecting those changes to consistent, meaningful outcomes across tissues and populations [8].
Second generation: making a natural message persist
Semaglutide and CJC-1295 share a design ambition: protect a short-lived biological message from rapid disappearance. Both use structural changes and albumin association to extend exposure. That similarity makes their different development histories revealing.
Semaglutide’s persistent GLP-1 signal progressed into large trials. The record includes a substantial mean weight difference versus placebo in STEP 1, fewer major cardiovascular events in SELECT, and fewer major kidney-disease events in FLOW [14][15][16]. Its safety literature is likewise large enough to identify gastrointestinal intolerance and biliary disease while naming cancer signals that remain unresolved [17].
CJC-1295’s persistent GHRH signal produced clear growth-hormone and IGF-1 changes in early studies [21][22]. Yet the program did not deliver comparable long-term or clinical-outcome evidence. The molecules demonstrate that pharmacokinetic success — keeping a signal present — and clinical success are different achievements.
Third generation: the multi-receptor question
Modern peptide development increasingly asks whether one molecule can coordinate several receptors. None of the four compounds here is itself a multi-receptor agent, but semaglutide provides the single-receptor benchmark. In a direct obesity trial, the dual GIP/GLP-1 agonist tirzepatide produced greater mean weight loss than semaglutide at seventy-two weeks [13]. That result suggests why designers add receptor arms: a second pathway may expand efficacy.
It does not prove that more targets are always better. Each receptor brings physiology, potential adverse effects, and new questions about balance. The history on this desk argues for evaluating multi-receptor designs with the same ladder used everywhere else: binding and signaling, animal models, human pharmacology, controlled efficacy, clinical outcomes, and long-term safety. Skipping a rung makes the story faster, not stronger.
The verdict: evidence maturity is part of mechanism
Mechanism describes what a molecule does to biology. Evidence maturity describes how confidently that description can be connected to a human outcome. The two belong together. MOTS-c has an unusual origin and increasingly specific targets, but its human story is observational [1][2]. NAD+ precursor studies move a biomarker reliably, while the larger clinical claim remains inconsistent [8]. Semaglutide has crossed the outcome threshold in multiple large populations [14][15][16]. CJC-1295 has proven a sustained hormonal effect and little beyond it [21][22].
The most responsible comparison does not crown a winner. It gives each compound the claim its study design can carry — no more, no less.